Skip to content

Advertisement

  • Case report
  • Open Access
  • Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Pancreatic panniculitis in a patient with pancreatic-type acinar cell carcinoma of the liver – case report and review of literature

  • Sebastian Zundler1Email author,
  • Ramona Erber2,
  • Abbas Agaimy2,
  • Arndt Hartmann2,
  • Franklin Kiesewetter3,
  • Deike Strobel1,
  • Markus F. Neurath1 and
  • Dane Wildner1
Contributed equally
BMC Cancer201616:130

https://doi.org/10.1186/s12885-016-2184-6

Received: 8 February 2015

Accepted: 16 February 2016

Published: 20 February 2016

Abstract

Background

Pancreatic panniculitis is a rare condition, which has only been described in relation with pancreatic diseases up to now. It is characterized by necrotizing subcutaneous inflammation and is thought to be triggered by adipocyte necrosis due to systemic release of pancreatic enzymes with consecutive infiltration of neutrophils. We present the first case of a patient with pancreatic panniculitis caused by pancreatic-type primary acinar cell carcinoma (ACC) of the liver and without underlying pancreatic disease.

Case presentation

A 73-year old Caucasian female patient was referred to our department with painful cutaneous nodules persisting for eight weeks and with marked lipasemia (~15000 U/l; normal range <60 U/l). Four weeks prior, several liver lesions had been detected. Empiric treatment with steroids did not show any effect. A biopsy of the skin nodules revealed “pancreatic” panniculitis, while abdominal imaging with ultrasound, computed tomography and magnetic resonance imaging detected no abnormal pancreatic findings. Ultrasound-guided biopsy of the liver lesions showed infiltrates of an ACC. The patient died soon thereafter. Autopsy failed to reveal any other primary for the ACC, so that a pancreatic-type ACC of the liver was diagnosed by exclusion.

One hundred thirty cases of pancreatic panniculitis published within the last 20 years are reviewed. ACC of the pancreas is the most common underlying neoplastic condition. Patients with associated neoplasm are significantly older, take longer to be diagnosed and have higher lipase levels than patients with underlying pancreatitis.

Extrapancreatic pancreatic-type ACC is very rare, but shows the same biological features as ACC of the pancreas. It is believed to develop from metaplastic or ectopic pancreatic tissue. Up to now, no pancreatic panniculitis in extrapancreatic ACC has been described.

Conclusion

Pancreatic panniculitis should always be included in the differential diagnosis of lipolytic panniculitic lesions. It can be regarded as a facultative paraneoplastic phenomenon.

When suspected, a thorough work-up for identification of the underlying disease is mandatory and extrapancreatic lesions (e.g. liver) should also be considered. While administration of octreotide or steroids can sometimes alleviate symptoms, immediate treatment of the associated condition is the only effective management option.

Keywords

Pancreatic panniculitisAcinar cell carcinomaPancreatitisParaneoplasticLipaseLiver

Background

Chiari was the first to describe the development of panniculitic lesions in patients with pancreatitis in 1883 [1]. Since then, several case reports and small case series have reported focal or generalized panniculitis in association with pancreatic diseases like acute or chronic pancreatitis, pancreatic carcinoma (ductal adenocarcinoma, acinar cell carcinoma, neuroendocrine carcinoma) or intraductal papillary mucinous neoplasm (IPMN) [26].

Up to 45 % of patients with pancreatic panniculitis show subcutaneous panniculitic nodules before the causal disease is recognized [2]. Therefore, these nodules can serve as an early and valuable clue to diagnosis of the underlying condition and trigger measurement of serum pancreatic enzymes, abdominal imaging or biopsy procedures. Histologic evaluation of the cutaneous lesions will typically reveal lobular neutrophilic necrotizing panniculitis intermingled with specific necrotic anucleate adipocytes called “ghost cells” [7].

The mechanism underlying the formation of panniculitic nodules in pancreatic panniculitis is poorly understood. However, it is commonly believed that systemically released pancreatic enzymes such as lipase and amylase cause distant lipolysis and fat necrosis with consecutive inflammatory reaction [8]. This is supported by the finding that the necrotic tissue stains positive for lipase [9]. However, serum levels of pancreatic enzymes do not correlate with clinical findings and similarly, in vitro experiments suggest that this explanation is not sufficient [10].

In addition to the cutaneous manifestation, arthritis is often found in patients with pancreatic panniculitis, clinically referred to as pancreatitis panniculitis polyarthritis (PPP) syndrome. It is thought that pancreatic enzymes are also able to trigger necrosis and inflammation in the synovium [11]. Furthermore, there are reports about panniculitis in the bone marrow, at submucosal sites or within the thoracic or peritoneal cavity [2, 11, 12].

Acinar cell carcinoma (ACC) is a rare pancreatic malignancy, representing about 1 % of all primary pancreatic neoplasms [13]. ACC is the most common malignancy found in patients with pancreatic panniculitis [14] and symptoms of pancreatic panniculitis can be found in up to 16 % of ACC patients [4]. On very rare occasions, pancreatic-type ACC can also arise as a primary neoplasm at extrapancreatic locations, such as liver, stomach, jejunum and colon [1518]. In such cases, extrapancreatic ACC is believed to originate from either ectopic, metaplastic of transdifferentiated pancreatic tissue and shares biologic features with primary pancreatic ACC [15].

Here, we report the first case of pancreatic panniculitis in association with a primary pancreatic-type ACC of the liver without underlying pancreatic disease. Moreover, we present a review of case reports and case series of pancreatic panniculitis from the last 20 years, summarizing important knowledge and data about this disease entity.

Case presentation

A 73-year-old Caucasian female patient was referred to our department for further work-up of painful cutaneous lesions (Fig. 1) and several masses within her liver.
Figure 1
Fig. 1

Several panniculitic lesions on the right leg of the patient, one of them (→) shortly after having spontaneously drained brownish-oily fluid

Eight weeks prior, she had observed an erythematous nodule on her right chest. Subsequently, similar cutaneous lesions had developed on her arms and legs, and later also on her buttocks and back. She did not report any abdominal complaints. Outpatient treatment with topical and systemic steroids based on a suspicion of erythema nodosum (EN) did not yield substantial effect.

Four weeks prior, several liver lesions had been detected by ultrasound and were interpreted as metastases of a previously treated breast cancer. Additional imaging with computed tomography (CT) and magnetic resonance imaging (MRI) had been carried out (Fig. 2) and confirmed the liver lesions.
Figure 2
Fig. 2

Imaging of the liver lesions (→) with ultrasound (a) and CT (b)

As the nodules on her skin continued to spread and became increasingly painful, she was presented to the Department of Dermatology in our clinic. There, another attempt of steroids and an intensified local therapy resulted in no improvement of her clinical condition. Due to raising inflammatory parameters a work-up for possible infectious causes and an antibiotic therapy with piperacillin/tazobactam, and later with meropenem were initiated. A colonoscopy revealed two small polyps, which were completely removed. Pancreatic enzymes were markedly elevated. A punch biopsy of one of the skin lesions was obtained showing a lobular necrotizing panniculitis with “ghost cells” compatible with pancreatic panniculitis (Fig. 3). CT, MRI and repeated ultrasound examinations (Fig. 4) did not reveal any pathological findings in the pancreas. In contrast enhanced CT multiple sharply-bounded liver lesions were visualized in both liver lobes. Compared with the CT obtained during outpatient care, the lesions had progressed in size and measured from 1 cm to 6 cm. The perfusion pattern was non-hypervascular and the density was hypointense, partly comparable with the density of water. No necrotic areas were described within the lesions.
Figure 3
Fig. 3

Biopsy from a skin lesion showing lobular neutrophilic, necrotizing panniculitis and so called “ghost cells” (→)

Figure 4
Fig. 4

Abdominal imaging showing no evidence of pancreatic pathology. a CT. b MRI. c ultrasound

Because of a progressive worsening of her clinical condition and increasing laboratory markers of inflammation, the patient was referred to our Department of Internal Medicine. She complained about intensive pain all over her skin and required increasing dose rates of opioid analgetics. She did not report any weight loss, night sweats, fever, nausea or vomiting, abdominal pain or problems with food intake. Her past medical history was remarkable for invasive ductal breast cancer diagnosed in 1982 with local recurrences in 1990 and 2008. Moreover, a superficial spreading malignant melanoma had been treated in 2011 and a coronary artery disease with percutaneous coronary intervention in 2008 was reported. Family history was significant for malignant melanomas in all siblings and her mother. Continuous medication included acetyl salicylic acid, lercanidipine, metoprolol, enalapril and pravastatin with no recent change. No allergic condition was known.

On examination she was in poor general condition (ECOG performance status 4), tachycardic (102 bpm), slightly tachypnoeic (22/min) and normotensive (128/78 mmHg). Her temperature was 36.9 °C. Subcutaneous erythematous and painful nodules of 2–5 cm size were noticed throughout her integument. Some of them were spontaneously draining a brownish oily fluid. Moreover, more than 200 melanocytic nevi were observed on her skin. Examination of the head, especially focusing on the salivary glands was unremarkable. There was no pain on abdominal palpation, the liver was palpable 2 cm under the right costal arch and bowel sounds were normal. There was a positive tap sign on both patellae.

Laboratory results of interest were: leukocyte count 21.5 * 10^3/μl (ref. 4–10 * 10^3/μl), hemoglobin 10.0 g/dl (ref. 12–16 g/dl), ASAT 52 U/l (ref. < 35U/l), GGT 235 U/l (ref. <40 U/l), AP 186 U/l (ref. 35–105 U/l), lipase 14747 U/l (ref. < 60 U/l) and CRP 237 mg/l (ref. < 5 mg/l). Alpha-Amylase, uric acid, ACE, CEA, CA19-9 and AFP were within normal range. Serology for Yersinia enterocolitica and pseudotuberculosis was negative, as well as testing for Mycobacterium tuberculosis and atypical mycobacteria. Rheumatologic testing including ANAs and ANCAs was unremarkable.

Screening for possible infectious foci did not reveal any other source explaining the elevated CRP. Therefore, it was attributed to the skin lesions, which displayed clinical signs of inflammation and were partly draining pus in the further course. However, as microbiological evaluation was not able to prove any causative organism and inflammation markers were not substantially declining despite escalation of antibiotic treatment with additional vancomycin, skin lesions were classified as sterile. Leukocytosis was explained by concomitant steroid therapy.

Ultrasound displayed several liver lesions in both lobes with a maximum size of 53 mm. The pancreas was homogeneous and free of focal lesions. The pancreatic duct was not dilated and no avascular areas could be detected upon administration of ultrasound contrast agent. Ultrasound-guided puncture of one of the liver masses was performed leading to the histopathological diagnosis of a pancreatic-type ACC.

Unfortunately, the condition of the patient had severely deteriorated in the meantime with further exacerbation of pain, increasing tachycardia and hypotension. Therefore, no tumor-specific treatment could be initiated. The patient died ten days after admission to our ward.

Pathological and autopsy findings

Histopathological analysis of the core biopsy obtained from the liver mass revealed a cellular epithelial neoplasm composed of monomorphic polygonal or rounded cells arranged in compact acinar and trabecular structures (Fig. 5a, b). Immunohistochemical study revealed strong expression of pancytokeratin (KL-1) with variable expression of CK7 and diffuse strong cytoplasmic expression of trypsin (Fig. 5c), but lipase and amylase were negative. All other markers in the differential diagnosis were negative (CK5, CK20, HepPar-1, Synaptophysin, Chromogranin A, NSE, CD56, TTF1, ER, PR, protein S100, GATA3 and PAX8). These findings including in particular the strong and specific expression of trypsin confirmed the diagnosis of pancreatic-type ACC in the liver.
Figure 5
Fig. 5

Histomorphology and immunohistochemistry of the liver tumor (from core biopsy). a core biopsy of the liver showing liver tissue adjacent to the acinar cell carcinoma, haematoxylin/eosin staining, 10-fold magnification. b compact acinar structures and trabeculae seen at higher magnification, haematoxylin/eosin staining, 40-fold magnification. c The tumor cells stained strongly for trypsin, 40-fold magnification

Autopsy confirmed several liver masses measuring up to six centimeters in size. There was no evidence of a salivary gland tumor or a primary pancreatic tumor. Additionally, review of the slides from the patient’s previous breast cancer confirmed a breast cancer of no special type and excluded the possibility of acinar-like differentiation. Thus, the previous breast cancer was also unrelated to the patient's ACC. Cause of her death was attributed to multiorgan failure due to severe systemic inflammatory response syndrome.

Final diagnosis was pancreatic panniculitis due to primary pancreatic-type acinar cell carcinoma of the liver.

Taking into account the conspicuous accumulation of malignancies in our patient and her family, genetic analysis for familial atypical multiple mole-melanoma (FAMMM) syndrome was recommended to her relatives.

Review of literature

In addition to the presented case, 130 reports on pancreatic panniculitis were identified in the English literature between January 1994 and November 2014 by using the search terms “pancreatic panniculitis”, “subcutaneous fat necrosis AND pancreas” and “lipase hypersecretion syndrome” in PubMed and by checking results for appropriate cross-references.

Including the above case, all 131 cases (Table 1) were analyzed in respect to available data on age and gender of the patients, the underlying condition, additional symptoms, the sequence of the appearance of panniculitis and the diagnosis of the underlying disease, laboratory values and the outcome. The stated percentages refer to the respective number of cases including data on the analyzed parameter. Statistical analysis was performed with IBM SPSS Statistics (IBM, Armonk, NY, USA) using Student’s T-test or Fisher’s exact test where applicable. p < 0.05 was considered significant. Graphs were generated with SigmaPlot (Systat, San Jose, CA, USA).
Table 1

Overview of pancreatic panniculitides described in English literature between January 1994 and November 2014

Patient

Ref.

Age

Sex

Underlying condition

Outcome of skin lesions/follow-up

1

our pat.

73

f

ACC of the liver

death ten weeks after first skin lesion

2

[53]

55

m

metastatic pancreatic NEC

n.r.

3

[54]

38

m

acute pancreatitis

resolution

4

[7]

63

m

acute pancreatitis

resolution

5

[55]

81

f

hemosuccus pancreaticus

death 19 weeks after first skin lesion

6

[56]

26

f

acute pancreatitis

resolution

7

[57]

27

f

acute pancreatitis

resolution

8

[58]

34

m

chronic pancreatitis

n.r.

9

[59]

63

f

acute pancreatitis

resolution

10

[60]

83

m

pancreatic ACC

resolution of skin lesions after surgery, death 34 months after first skin lesion

11

[60]

75

m

Acute pancreatitis

resolution

12

[60]

60

m

Large pancreatic neoplasm

n.r.

13

[61]

68

f

metastatic pancreatic ACC

death six months after first skin lesion

14

[62]

61

f

acute pancreatitis

resolution

15

[63]

63

f

acute pancreatitis

resolution

16

[64]

49

m

acute pancreatitis

resolution

17

[47]

69

m

hepatic metastasis of previous-ly resected pancreatic ACC

resolution after metastasectomy, follow-up n.r.

18

[65]

71

f

chronic pancreatitis with pseudocyst

n.r.

19

[66]

66

f

serous cystadenoma of the pancreas

n.r.

20

[67]

39

m

chronic pancreatitis

death six weeks after first skin lesion

21

[68]

20

f

pseudopapillary pancreatic tumor, chronic pancreatitis

death eleven weeks after first skin lesion

22

[8]

38

f

acute pancreatitis

resolution

23

[69]

56

f

acute pancreatitis

death within a few days

24

[70]

79

m

pancreatic ACC

n.r.

25

[71]

17

f

acute pancreatitis

resolution

26

[72]

54

m

pancreatic ACC

Response to octreotide, regression of skin lesions after resection, follow-up two months (i.e. eleven months after first skin lesion)

27

[73]

81

f

pancreatic tumor with hepatic metastases

n.r.

28

[74]

64

m

anastomotic leakage after Whipple procedure

death 50 days after first skin lesion

29

[75]

79

f

pancreatic ACC

regression after resection, follow-up 14 months after resection (i.e. 16 months after first skin lesion)

30

[35]

60

f

pancreatic adenocarcinoma

n.r.

31

[35]

58

m

malignant neoplasia of the tail of the pancreas

n.r.

32

[76]

44

f

pancreas transplant rejection

resolution

33

[77]

63

f

metastatic pancreatic adenocarcinoma

n.r.

34

[78]

38

m

pancreatic pseudocyst-inferior vena cava fistula

resolution after Roux-en-Y pseudocyst-jejunostomy

35

[40]

82

m

pancreatic ACC

death 2.5 months after first skin lesion

36

[46]

79

m

pancreatic ACC

death two months after first skin lesion

37

[79]

2,5

m

acute pancreatitis with pseudocyst

n.r.

38

[80]

45

m

chronic pancreatitis

resolution after placement of endoprothesis

39

[81]

18

w

acute pancreatitis

resolution

40

[82]

10

w

acute pancreatitis with pseudocyst

resolution after endosonographic cysto-gastrostomy

41

[83]

69

m

gastric adenocarcinoma with pancreas metastasis

death 14 weeks after first skin lesion

42

[84]

58

m

pancreatic pseudocyst-portal vein fistula

death five days after admission

43

[85]

84

m

pancreatic tumor

death two months after first skin lesion

44

[86]

40

m

chronic pancreatitis

n.r.

45

[87]

84

f

acute pancreatitis, liver lesions ten years after resection of colonic carcinoma

initially resolution, death three months later

46

[2]

65

f

acute pancreatitis

death from gangrenous cholecystitis

47

[2]

64

f

acute pancreatitis

resolution

48

[2]

70

f

pancreatic carcinoma

death

49

[2]

58

m

pancreatic carcinoma

death

50

[2]

21

f

pancreatic carcinoma

death

51

[2]

75

m

acute pancreatitis

death

52

[2]

75

f

acute pancreatitis

resolution

53

[2]

44

m

chronic pancreatitis

resolution

54

[2]

63

m

pancreatic carcinoma

death

55

[2]

72

m

pancreatic carcinoma

death

56

[2]

60

m

pancreatic carcinoma

n.r.

57

[88]

35

m

chronic pancreatitis

n.r.

58

[89]

7

m

acute pancreatitis

resolution

59

[14]

61

m

metastatic NEC of unknown primary site

death a few weeks after first skin lesion

60

[42]

50

f

metastatic ACC

regression of skin lesions and tumor under octreotide, gemcitabine, streptozocin and doxorubicin; return after discontinuation; response to restart of therapy; follow-up 9 months after first skin lesion

61

[90]

74

m

pancreatic ACC

death 3.75 months after first skin lesion

62

[91]

61

m

metastatic ACC

n.r.

63

[92]

79

m

metastatic pancreatic NEC

Regression under cefazolin, dexamethasone and NSAID; death 13 months after first skin lesion

64

[93]

50

m

acute pancreatitis

death 38 days after first skin lesion

65

[94]

4

m

acute pancreatitis

resolution

66

[11]

45

m

acute pancreatitis

Regression under NSAID and prednisone

67

[95]

72

m

acute pancreatitis

resolution

68

[96]

52

f

pancreatic carcinoma

death six months after first skin lesion

69

[97]

29

m

acute pancreatitis

resolution

70

[23]

75

f

hepatic metastases of adeno-carcinoma of unknown origin

death 15 weeks after first skin lesion

71

[6]

78

m

metastatic pancreatic NEC

death two months after first skin lesion

72

[6]

75

m

pancreatic adenocarcinoma

regression under irradiation, follow-up n.r.

73

[98]

67

f

IPMN

partial pancreatectomy, follow-up n.r.

74

[99]

51

m

chronic pancreatitis

regression of skin lesions under conservative treatment

75

[100]

49

f

pancreas transplant rejection

resolution

76

[101]

89

f

acute pancreatitis

resolution

77

[42]

59

m

hepatic metastases of pre-viously resected pancreatic ACC

death several weeks after first skin lesion

78

[102]

67

m

metastatic pancreatic adenocarcinoma

regression under irinotecan, cisplatin, mito-mycin; death twelve months after first skin lesion

79

[103]

62

f

IPMN

resection, follow-up n.r.

80

[22]

60

m

metastatic pancreatic acinar cell cystadenocarcinoma

death seven weeks after admission

81

[104]

13

m

chronic pancreatitis with pseudocyst

regression after cystogastrostomy

82

[41]

72

m

pancreatic NEC

regression after resection, no reappearance with liver metastases, death 15 months after first skin lesion

83

[25]

58

m

HCC

death four months after first skin lesion

84

[105]

88

m

metastatic pancreatic NEC

Death eight weeks after first skin lesion

85

[106]

42

f

acute pancreatitis

resolution

86

[107]

63

m

chronic pancreatitis

resolution after distal pancreatectomy and pancreatic duct dilation

87

[108]

34

m

acute pancreatitis

resolution

88

[109]

21

f

acute pancreatitis

death from retroperitoneal hemorrhage

89

[110]

61

f

metastatic pancreatic ACC

death one year after first skin lesion

90

[3]

70

f

IPMN

resolution after resection

91

[3]

53

f

IPMN

resolution after resection

92

[111]

37

f

acute pancreatitis with pseudocyst

resolution after surgery

93

[111]

50

m

acute pancreatitis with pseudocyst

resolution after stone extraction from the pancreatic duct

94

[112]

71

m

pancreatic adenocarcinoma

n.r.

95

[113]

60

f

pancreatic ACC

regression after distal pancreatectomy, follow-up 28 months after first skin lesion

96

[113]

54

m

pancreatic ACC

death six weeks after first skin lesion

97

[114]

56

m

chronic pancreatitis

n.r.

98

[115]

53

m

actue pancreatitis

resolution

99

[48]

67

m

metastatic pancreatic ACC

Regression after TACE of four liver metasta-ses, death 14 weeks after first skin lesion

100

[116]

n.r.

n.r.

chronic pancreatitis

resolution after placement of pancreatic duct stent

101

[117]

31

m

acute pancreatitis

resolution

102

[118]

57

f

acute pancreatitis

resolution

103

[119]

60

f

pancreatic ACC

resolution after resection, follow-up n.r.

104

[120]

41

m

acute pancreatitis

death 22 days after admission

105

[44]

79

f

metastatic pancreatic ACC

Death 20 weeks after first skin lesion

106

[121]

45

m

chronic pancreatitis

resolution

107

[122]

59

f

acute pancreatitis

resolution

108

[123]

81

m

pancreatic ACC

n.r.

109

[124]

69

m

pancreatic ACC

n.r.

110

[125]

15

f

acute pancreatitis

death nine days after first skin lesion

111

[126]

49

m

acute pancreatitis

regression under antibiotic treatment, then slight progression, follow-up seven weeks

112

[127]

66

m

pancreatic ACC

resolution after resection, follow-up n.r.

113

[128]

67

m

chronic pancreatitis

death two months after first skin lesion

114

[12]

69

m

pancreatic ACC

resolution after distal pancreatectomy and adjuvant radio-chemotherapy, follow-up 6 months

115

[129]

29

f

acute pancreatitis

resolution

116

[130]

29

m

pancreatic pseudocyst-portal vein fistula

no new lesions after surgery

117

[131]

75

m

pancreatic tumor

Death several months after first skin lesion

118

[131]

39

m

chronic pancreatitis with pseudocyst

n.r.

119

[132]

62

m

acute pancreatitis

resolution

120

[133]

77

f

pancreatic tumor

death five months after first skin lesion

121

[134]

54

f

chronic pancreatitis

resolution after ESWL and endoscopic dilation of the pancreatic duct

122

[135]

47

f

acute pancreatitis

resolution

123

[136]

7

m

acute pancreatitis

n.r.

124

[137]

69

m

chronic pancreatitis with pseudocyst

resolution

125

[138]

33

f

acute pancreatitis

n.r.

126

[139]

46

f

chronic pancreatitis

death four months after first skin lesion

127

[140]

55

m

chronic pancreatitis

n.r.

128

[5]

62

m

acute pancreatitis

resolution

129

[141]

61

f

metastatic ACC

resolution after surgery, follow-up n.r.

130

[142]

80

m

pancreatic ACC

resolution after surgery, death from metastatic disease after 18 months

131

[143]

n.r.

m

pancreatic ACC

n.r.

Overall, 65 cases (49.6 %) were due to acute or chronic pancreatitis and 60 cases (45.8 %) had an underlying neoplastic condition. In six cases (4.6 %) other reasons were present, e.g. pancreas transplant rejection or pancreaticovascular fistula (Table 2).
Table 2

Etiology of pancreatic panniculitis

Pancreatitis

Neoplastic conditions

Other

Acute

34.4 %

pancreatic ACC

19.8 %

fistula

2.3 %

Chronic

15.3 %

n. r.

9.9 %

transplant rejection

1.5 %

  

NEC

4.6 %

 
  

adeno-carcinoma

3.8 %

anastomotic leakage

0.8 %

  

IPMN

3.1 %

  
  

other

4.6 %

  

Total

49.6 %

total

45.8 %

total

4.6 %

While near half of the cases are caused by acute or chronic pancreatitis, another 45.8 % are associated with neoplastic conditions (other: acinar cystadenocarcinoma, ACC of the liver, serous cystadenoma, HCC, gastric carcinoma with pancreatic infiltration, adenocarcinoma of unknown primary)

Patients with pancreatic panniculitis had a mean age of 54.8 years. Yet, patients with neoplastic causes were significantly older than individuals with pancreatitis (Fig. 6a). 57.4 % of the patients were male with no difference in sex distribution between underlying pancreatitis and malignancy.
Figure 6
Fig. 6

Comparison of patients with pancreatitis and neoplasm underlying pancreatic panniculitis (a-c): a Patients with neoplastic conditions are significantly older than patients with pancreatitis (66.0 +/− 13.0 years vs. 44.7 +/− 20.5 years, p < 0.001). b Underlying malignancy is diagnosed significantly later than underlying pancreatitis (134 +/− 135 days vs. 20 +/− 26 days, p < 0.001). c Tumor patients have significantly higher lipase levels than pancreatitis patients (16611 +/− 20772 vs. 5324 +/− 14436 U/l, p < 0.01). d Kaplan-Meier plot of survival after appearance of the first panniculitis lesion in patients with pancreatic panniculitis associated with malignancy. Median survival is 4.75 months (n = 29)

In 48.9 %, cutaneous lesions were noted prior to the diagnosis of the underlying disease. The mean duration from appearance of the first lesion to diagnosis was 85 days +/− 110 days (range: 2–540 days; median 42 days). This period was significantly longer when pancreatic panniculitis was due to a neoplasm than when a pancreatitis was present (Fig. 6b). Moreover, the portion of patients developing panniculitis before the diagnosis of the underlying condition was by trend higher in patients with neoplastic disease (66.7 %) than in patients with pancreatitis (48.3 %; p = 0.06).

A PPP syndrome with additional signs of arthritis was present in 49 cases (37.4 %).

One hundred twelve case reports (85.5 %) contained information on the serum levels of at least one pancreatic enzyme. In all but two of these reports (1.8 %) either amylase or lipase were elevated – in one of these two cases only amylase had been measured. The mean level of lipase was 11560 U/l +/− 19010 U/l (range 7–89700 U/l, median 3942.5 U/l). Again, patients with pancreatitis and neoplastic conditions differed markedly with tumor patients having significantly higher lipase levels (Fig. 6c). ROC analysis identified a lipase level of 4414 U/l as best cut-off value with higher values having a sensitivity of 73.0 % and a specificity of 82.1 % for the diagnosis of a neoplastic cause (AUC = 0.785, 95 % CI 0.68 to 0.89).

Only limited data was available concerning survival and follow-up. 12 patients with pancreatitis (21.4 %) died from complications. For underlying malignancy, follow-up data was available for 29 patients. A Kaplan-Meier plot of survival was computed, yielding a median survival of 4.75 months after appearance of the first skin lesion (Fig. 6d).

Discussion

Panniculitis is a clinical finding, which can be caused by various etiologic factors including infectious, immunologic and neoplastic conditions [1921].

In our case, numerous causes could be excluded, while others were very unlikely: No infectious organism could be detected directly or indirectly. Continuous medication was unchanged and unsuspicious for causing erythema nodosum. Imaging had not yielded any evidence of malignancy other than the finally diagnosed ACC. Rheumatologic disease was judged unlikely based on consultation with a rheumatologist.

Therefore, regarding laboratory data and histologic results pancreatic panniculitis was the only possible diagnosis.

Our case of pancreatic panniculitis is noteworthy for two reasons: The absence of pancreatic disease and the extrapancreatic manifestation of pancreatic-type ACC. The combination of both has not been previously described in the literature. Pancreatic panniculitis without definite proof of pancreatic disease is found in four cases in the literature: Beltraminelli et al. [22] report a case of acinar cell cystadenocarcinoma of presumably pancreatic origin metastatic to the liver. However, clear evidence of a pancreatic primary tumor was absent on imaging. Freireich-Astmann et al. [23] describe the history of a patient with hepatic metastases of an adenocarcinoma of unknown primary. CT did not show any pancreatic lesion and immunohistochemistry was negative for CA19-9 and CK19. Aznar-Oroval et al. present a case of gastric adenocarcinoma with hepatic metastases in association with pancreatic panniculitis, but without clinical or radiologic findings of pancreatic disease [24]. And finally, Corazza et al. [25] report about a patient with multifocal hepatocellular carcinoma (HCC) and missing pancreatic lesions in CT.

However, in all cases, no autopsy for definite verification of the absence of pancreatic disease was performed. Amylase or lipase were elevated in each of the cases, but could not be explained by clinical, radiologic or histological findings in all but Beltraminelli et al.’s case. While existence of a primary hepatic acinar cell cystadenocarcinoma should have been discussed in this case, findings are inconclusive in the other three.

The HCC described by Corazza showed “trabecular structures and acinar aspects”, features suggestive of or consistent with ACC [15]. As immunohistochemistry is not reported, the possibility of a pancreatic-type ACC of the liver cannot be fully excluded in that case.

Primary extrapancreatic ACC is extremely rare and only six cases of ACC originating in the liver have been described to date [15, 26, 27]. Diagnosis of pancreatic-type ACC originating from the liver requires exclusion not only of an occult pancreatic primary, but also of primaries at other possible sites, such as breast [28] or salivary glands [29]. In our case, neither clinical nor radiological evidence for another primary was present, which was finally verified by autopsy findings. Moreover, re-analysis of the samples of the previously treated breast cancer excluded a hitherto undiscovered acinar cell carcinoma of the breast.

Because of the rarity of primary ACC of the liver, no typical pattern can be specified in the different imaging modalities up to now. So far, most of the cases described were initially misclassified as one of the most common primary liver malignancies, such as HCC or cholangiocellular carcinoma (CCC), due to their imaging appearance. Moreover, a recent study on imaging findings in pancreatic ACC also reported a high variability in several parameters analyzed [30]. Thus, a thorough histological work-up of specimens after a resection or core biopsy is required to ensure the correct diagnosis [15, 26, 27].

What could be objected to the diagnosis of an ACC of the liver in our case is the multifocality of the liver lesions, which is suggestive for metastatic disease. However, despite thorough work-up no other primary was found. Furthermore, it is worth noting that ACC is normally relatively large in size by the time of diagnosis [4], which makes an occult primary rather unlikely. In addition, multifocal growth of primary liver tumors is not unusual, e.g. in intrahepatic CCC [31, 32] and HCC [33, 34]. Indeed, primary hepatic ACC might originate from acinar trans-differentiation of biliary progenitor cells, thus representing the acinar counterpart of hepatic cholangiocarcinoma [15].

In an analysis of more than 130 cases of pancreatic panniculitis described in the last 20 years, we could show that nearly half of the cases are associated with an internal malignancy. Current concepts of the pathogenesis of pancreatic panniculitis suggest a role of pancreatic enzymes produced or released by these tumors [8, 9]. Therefore – though only rarely so named [35] – pancreatic panniculitis should be regarded as facultative paraneoplastic condition [36] and a tumor screening, especially for pancreatic tumors, should always be included in the diagnostic work-up.

The analysis of different parameters of these cases revealed significant differences between patients with pancreatic panniculitis and associated neoplasm or pancreatitis. On average, patients with a tumor are older and have higher lipase levels. Moreover, it takes longer until a diagnosis is made in these cases. A lipase cut-off value of 4414 U/l is able to differentiate between underlying pancreatitis and neoplasm with a sensitivity and specificity comparable with CA 19–9 in ductal adenocarcinoma vs. benign pancreatic disease [37].

Regarding the epidemiology and the natural course of malignancy and pancreatitis these results are not very surprising. However, these items can provide a first orientation, which etiology has to be primarily suspected. Like this, they may trigger a particularly intensive search for tumors in older patients with high lipase levels and a long-lasting history of panniculitis.

This is even more important as pancreatic panniculitis seems to be a hallmark of poor prognosis in tumor patients. Median survival in the cases with underlying malignancy and included follow-up data was 4.75 months after appearance of the first skin lesion.

Of course, this retrospective analysis has significant limitations as it is exclusively based on case reports. Though, it is the first systematic evaluation of survival in pancreatic panniculitis and poor outcome is remarkable, because over 50 % of the included cases were ACC patients, which otherwise have considerably better survival [38, 39].

Due to the rarity of the disease, clear therapeutic algorithms for ACC are missing. Since most of the cases present with distant metastases only a subset of patients qualifies for resection [39]. Therefore, cancer therapy is often limited to palliative approaches like chemotherapy or ablative treatment. As in our case, patients often suffer heavily from the pain caused by their skin lesions and analgetic therapy is frequently not sufficiently able to reduce pain [12, 14, 22, 40, 41]. Thus, palliative treatment strategies are very important for symptom control as well.

Octreotide has been reported to alleviate symptoms in some cases [4244]. Chemotherapeutic agents reported to be used in patients with pancreatic panniculitis and underlying ACC include gemcitabine and the FOLFIRI regime [45, 46]. Furthermore, one case with resolution of panniculitis following metastasectomy [47] and one case with marked symptom reduction after transarterial chemoembolization (TACE) of hepatic metastases [48] are described in literature. Some success in the treatment of pancreatic ACC has been reported with the use of FOLFOX [49], FOLFIRINOX [50], cisplatin/etoposide [51] and gemcitabine in various combinations including erlotinib [52].

Conclusion

To our best knowledge, this is the first report of pancreatic panniculitis in a patient with primary ACC of the liver.

The possibility of pancreatic panniculitis should always be included in diagnostic considerations regarding panniculitic lesions. Therefore, a cutaneous biopsy should be obtained, pancreatic enzymes should be measured and abdominal imaging should be performed as early as possible. When diagnosed, pancreatic panniculitis has to be regarded as a facultative paraneoplastic syndrome and appropriate tumor screening or biopsy procedures have to be undertaken. This is especially important in older patients with high lipase levels and long-lasting symptoms. Regarding the presented case, tumors of extrapancreatic primary must also be considered.

Pancreatic-type ACC is the malignancy most often associated with pancreatic panniculitis. It can not only originate from the pancreas but also from the liver, which can be diagnosed, when other primary sites have been excluded.

Pancreatic panniculitis in association with malignancy seems to be linked with poor prognosis. Thus, early diagnosis is necessary to improve survival and ease symptoms, e.g. by resection or chemotherapy. Symptomatic therapy with octreotide seems worth trying. Further studies are required to define standard therapeutic strategies for unresectable ACC.

Consent

During her lifetime, the patient consented orally to the use of her patient history and all the related images and information for scientific purposes. After the patient’s death her daughter gave written consent for the publication of the case.

Abbreviations

ACC: 

acinar cell carcinoma

ACE: 

angiotensin-converting enzyme

AFP: 

alpha fetoprotein

ANA: 

anti-nuclear antibody

ANCA: 

anti-neutrophil cytoplasmatic antibody

AP: 

alkaline phosphatase

AST: 

aspartate transaminase

CA 19–9: 

carbohydrate antigen 19–9

CCC: 

cholangiocellular carcinoma

CEA: 

carcinoembryonic antigen

CK: 

cytokeratin

CRP: 

c-reactive protein

CT: 

computed tomography

ECOG: 

Eastern cooperative oncology group

EN: 

erythema nodosum

ESWL: 

extracorporal shock wave lithotripsy

f: 

female

FOLFIRI: 

folinic acid, 5-fluoruracil, irinotecan

FOLFIRINOX: 

folinic acid, 5-fluoruracil, irinotecan, oxaliplatin

FOLFOX: 

folinic acid, 5-fluoruracil, oxaliplatin

GGT: 

gamma glutamyl transferase

HCC: 

hepatocellular carcinoma

IPMN: 

intraductal papillar mucinous neoplasm

m: 

male

MRI: 

magnetic resonance imaging

n.r.: 

not reported

NEC: 

neuroendocrine carcinoma

NSAID: 

non-steroidal anti-inflammatory drugs

PPP syndrome: 

pancreatitis panniculitis polyarthritis syndrome

TACE: 

transarterial chemoembolization

Declarations

Acknowledgements

We acknowledge support by Deutsche Forschungsgemeinschaft and Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU) within the funding programme Open Access Publishing.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Department of Medicine 1, University Hospital Erlangen, Erlangen, Germany
(2)
Institute of Pathology, University Hospital Erlangen, Erlangen, Germany
(3)
Department of Dermatology, University Hospital Erlangen, Erlangen, Germany

References

  1. Chiari H: Über die sogenannte Fettnekrose. Prag Med Wochenschr 1883;8:255–6.Google Scholar
  2. Dahl PR, Su WP, Cullimore KC, Dicken CH. Pancreatic panniculitis. J Am Acad Dermatol. 1995;33:413–7.PubMedView ArticleGoogle Scholar
  3. Le Borgne J, Partensky C, Dupas B, Chavaillon A. Weber-Christian syndrome revealing intraductal papillary mucinous tumor of the pancreas. Pancreas. 1999;18:322–4.PubMedView ArticleGoogle Scholar
  4. Klimstra DS, Heffess CS, Oertel JE, Rosai J. Acinar cell carcinoma of the pancreas. A clinicopathologic study of 28 cases. Am J Surg Pathol. 1992;16:815–37.PubMedView ArticleGoogle Scholar
  5. Rani M, Kaka A. Lobular Panniculitis. N Engl J Med. 2013;368:465–5.PubMedView ArticleGoogle Scholar
  6. Marsh RW, Hagler KT, Carag HR, Flowers FP. Pancreatic panniculitis. Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol. 2005;31:1213–5.Google Scholar
  7. Laureano A, Mestre T, Ricardo L, Rodrigues AM, Cardoso J. Pancreatic panniculitis - a cutaneous manifestation of acute pancreatitis. J Dermatol Case Rep. 2014;8:35–7.PubMedPubMed CentralView ArticleGoogle Scholar
  8. Hu JC, Gutierrez MA. Pancreatic panniculitis after endoscopic retrograde cholangiopancreatography. J Am Acad Dermatol. 2011;64:e72–4.PubMedView ArticleGoogle Scholar
  9. Dhawan SS, Jimenez-Acosta F, Poppiti RJ, Barkin JS. Subcutaneous fat necrosis associated with pancreatitis: histochemical and electron microscopic findings. Am J Gastroenterol. 1990;85:1025–8.PubMedGoogle Scholar
  10. Berman B, Conteas C, Smith B, Leong S, Hornbeck L. Fatal pancreatitis presenting with subcutaneous fat necrosis. Evidence that lipase and amylase alone do not induce lipocyte necrosis. J Am Acad Dermatol. 1987;17(2 Pt 2):359–64.PubMedView ArticleGoogle Scholar
  11. Narváez J, Bianchi MM, Santo P, de la Fuente D, Ríos-Rodriguez V, Bolao F, Narváez JA, Nolla JM. Pancreatitis, Panniculitis, and Polyarthritis. Semin Arthritis Rheum. 2010;39:417–23.Google Scholar
  12. Ashley SW, Lauwers GY. Case 37–2002. N Engl J Med. 2002;347:1783–91.PubMedView ArticleGoogle Scholar
  13. Butturini G, Pisano M, Scarpa A, D’Onofrio M, Auriemma A, Bassi C. Aggressive approach to acinar cell carcinoma of the pancreas: a single-institution experience and a literature review. Langenbecks Arch Surg. 2011;396:363–9.PubMedView ArticleGoogle Scholar
  14. Martin SK, Agarwal G, Lynch GR. Subcutaneous fat necrosis as the presenting feature of a pancreatic carcinoma: the challenge of differentiating endocrine and acinar pancreatic neoplasms. Pancreas. 2009;38:219–22.PubMedView ArticleGoogle Scholar
  15. Agaimy A, Kaiser A, Becker K, Bräsen J-H, Wünsch PH, Adsay NV, Klöppel G. Pancreatic-type acinar cell carcinoma of the liver: a clinicopathologic study of four patients. Mod Pathol Off J U S Can Acad Pathol Inc. 2011;24:1620–6.Google Scholar
  16. Lee H, Tang LH, Veras EF, Klimstra DS. The prevalence of pancreatic acinar differentiation in gastric adenocarcinoma: report of a case and immunohistochemical study of 111 additional cases. Am J Surg Pathol. 2012;36:402–8.PubMedView ArticleGoogle Scholar
  17. Sun Y, Wasserman PG. Acinar cell carcinoma arising in the stomach: a case report with literature review. Hum Pathol. 2004;35:263–5.PubMedView ArticleGoogle Scholar
  18. Makhlouf HR, Almeida JL, Sobin LH. Carcinoma in jejunal pancreatic heterotopia. Arch Pathol Lab Med. 1999;123:707–11.PubMedGoogle Scholar
  19. Requena L, Yus ES. Panniculitis. Part I. Mostly septal panniculitis. J Am Acad Dermatol. 2001;45:163–83. quiz 184–186.PubMedView ArticleGoogle Scholar
  20. Requena L, Sánchez Yus E. Panniculitis. Part II. Mostly lobular panniculitis. J Am Acad Dermatol. 2001;45:325–61. quiz 362–364.PubMedView ArticleGoogle Scholar
  21. Requena L, Requena C. Erythema nodosum. Dermatol Online J 2002, 8:4.Google Scholar
  22. Beltraminelli HS, Buechner SA, Häusermann P. Pancreatic panniculitis in a patient with an acinar cell cystadenocarcinoma of the pancreas. Dermatol Basel Switz. 2004;208:265–7.View ArticleGoogle Scholar
  23. Freireich-Astman M, Segal R, Feinmesser M, David M. Pancreatic panniculitis as a sign of adenocarcinoma of unknown origin. Isr Med Assoc J IMAJ. 2005;7:474–5.PubMedGoogle Scholar
  24. Aznar-Oroval E, Illueca-Ballester C, Sanmartín-Jiménez O, Martínez-Lapiedra C, Santos-Corés J. Paniculitis pancreática como forma de presentación inicial de adenocarcinoma gástrico con metástasis hepáticas. Rev Esp Patol. 2013;46:40–4.Google Scholar
  25. Corazza M, Salmi R, Strumia R. Pancreatic Panniculitis as a First Sign of Liver Carcinoma. Acta Derm Venereol. 2003;83:230–1.PubMedView ArticleGoogle Scholar
  26. Wildgruber M, Rummeny E-J, Gaa J. Primary acinar cell carcinoma of the liver. RöFo Fortschritte Auf Dem Geb Röntgenstrahlen Nukl. 2013;185:572–3.View ArticleGoogle Scholar
  27. Hervieu V, Lombard-Bohas C, Dumortier J, Boillot O, Scoazec J-Y. Primary acinar cell carcinoma of the liver. Virchows Arch. 2008;452:337–41.PubMedView ArticleGoogle Scholar
  28. Shingu K, Ito T, Kaneko G, Itoh N. Primary acinic cell carcinoma of the breast: a clinicopathological and immunohistochemical study. Case Rep Oncol Med. 2013;2013:372947.PubMedPubMed CentralGoogle Scholar
  29. Sessa S, Ziranu A, Di Giacomo G, Giovanni A, Maccauro G. A rare case of iliac crest metastasis from acinic cell carcinoma of parotid gland. World J Surg Oncol. 2014;12:48.PubMedPubMed CentralView ArticleGoogle Scholar
  30. Tian L, Lv X, Dong J, Zhou J, Zhang Y, Xi S, Zhang R, Xie C. Clinical features and imaging findings of pancreatic acinar cell carcinoma. Int J Clin Exp Med. 2015;8:14846–54.Google Scholar
  31. Herber S, Otto G, Schneider J, Manzl N, Kummer I, Kanzler S, Schuchmann A, Thies J, Düber C, Pitton M. Transarterial chemoembolization (TACE) for inoperable intrahepatic cholangiocarcinoma. Cardiovasc Intervent Radiol. 2007;30:1156–65.Google Scholar
  32. D’Onofrio M, Vecchiato F, Cantisani V, Barbi E, Passamonti M, Ricci P, Malagò R, Faccioli N, Zamboni G, Pozzi Mucelli R. Intrahepatic peripheral cholangiocarcinoma (IPCC): comparison between perfusion ultrasound and CT imaging. Radiol Med (Torino). 2008;113:76–86.Google Scholar
  33. Goh BKP, Chow PKH, Teo J-Y, Wong J-S, Chan C-Y, Cheow P-C, Chung AYF, Ooi LLPJ. Number of nodules, Child-Pugh status, margin positivity, and microvascular invasion, but not tumor size, are prognostic factors of survival after liver resection for multifocal hepatocellular carcinoma. J Gastrointest Surg Off J Soc Surg Aliment Tract. 2014;18:1477–85.Google Scholar
  34. Barman PM, Sharma P, Krishnamurthy V, Willatt J, McCurdy H, Moseley RH, Su GL. Predictors of mortality in patients with hepatocellular carcinoma undergoing transarterial chemoembolization. Dig Dis Sci. 2014;59:2821–5.Google Scholar
  35. Ortega-Loayza AG, Ramos W, Gutierrez EL. Paz PC de, Bobbio L, Galarza C: Cutaneous manifestations of internal malignancies in a tertiary health care hospital of a developing country. An Bras Dermatol. 2010;85:736–42.PubMedView ArticleGoogle Scholar
  36. McLean DI. Toward a definition of cutaneous paraneoplastic syndrome. Clin Dermatol. 1993;11:11–3 [Cutaneous Paraneoplastic Syndromes].PubMedView ArticleGoogle Scholar
  37. Poruk K, Gay D, Brown K, Mulvihill J, Boucher K, Scaife C, Firpo M, Mulvihill S. The clinical utility of CA 19–9 in pancreatic adenocarcinoma: diagnostic and prognostic updates. Curr Mol Med. 2013;13:340–51.Google Scholar
  38. Kitagami H, Kondo S, Hirano S, Kawakami H, Egawa S, Tanaka M. Acinar Cell Carcinoma of the Pancreas: Clinical Analysis of 115 Patients From Pancreatic Cancer Registry of Japan Pancreas Society. Pancreas. 2007;35:42–6.PubMedView ArticleGoogle Scholar
  39. Wisnoski NC, Townsend Jr CM, Nealon WH, Freeman JL, Riall TS. 672 patients with acinar cell carcinoma of the pancreas: a population-based comparison to pancreatic adenocarcinoma. Surgery. 2008;144:141–8.PubMedView ArticleGoogle Scholar
  40. Borowicz J, Morrison M, Hogan D, Miller R. Subcutaneous fat necrosis/panniculitis and polyarthritis associated with acinar cell carcinoma of the pancreas: a rare presentation of pancreatitis, panniculitis and polyarthritis syndrome. J Drugs Dermatol JDD. 2010;9:1145–50.PubMedGoogle Scholar
  41. Berkovic D, Hallermann C. Carcinoma of the Pancreas with Neuroendocrine Differentiation and Nodular Panniculitis. Onkologie. 2003;26:473–6.PubMedGoogle Scholar
  42. Bogart MM, Milliken MC, Patterson JW, Padgett JK. Pancreatic panniculitis associated with acinic cell adenocarcinoma: a case report and review of the literature. Cutis. 2007;80:289–94.PubMedGoogle Scholar
  43. Durden FM, Variyam E, Chren MM. Fat necrosis with features of erythema nodosum in a patient with metastatic pancreatic carcinoma. Int J Dermatol. 1996;35:39–41.PubMedView ArticleGoogle Scholar
  44. Hudson-Peacock MJ, Regnard CF, Farr PM. Liquefying panniculitis associated with acinous carcinoma of the pancreas responding to octreotide. J R Soc Med. 1994;87:361–2.PubMedPubMed CentralGoogle Scholar
  45. Antoine M, Khitrik-Palchuk M, Saif MW. Long-term survival in a patient with acinar cell carcinoma of pancreas. A case report and review of literature. JOP J Pancreas. 2007;8:783–9.Google Scholar
  46. Iwatate M, Matsubayashi H, Sasaki K, Kishida N, Yoshikawa S, Ono H, Maitra A. Functional pancreatic acinar cell carcinoma extending into the main pancreatic duct and splenic vein. J Gastrointest Cancer. 2012;43:373–8.Google Scholar
  47. Banfill KE, Oliphant TJ, Prasad KR. Resolution of pancreatic panniculitis following metastasectomy. Clin Exp Dermatol. 2012;37:440–1.PubMedView ArticleGoogle Scholar
  48. Riediger C, Mayr M, Berger H, Becker K, Dobritz M, Kleeff J, Friess H. Transarterial chemoembolization of liver metastases as symptomatic therapy of lipase hypersecretion syndrome. J Clin Oncol Off J Am Soc Clin Oncol. 2012;30:e209–212.Google Scholar
  49. Simon M, Bioulac-Sage P, Trillaud H, Blanc J-F. FOLFOX regimen in pancreatic acinar cell carcinoma: Case report and review of the literature. Acta Oncol. 2011;51:403–5.PubMedView ArticleGoogle Scholar
  50. Schempf U, Sipos B, König C, Malek NP, Bitzer M, Plentz RR. FOLFIRINOX as first-line treatment for unresectable acinar cell carcinoma of the pancreas: a case report. Z Für Gastroenterol. 2014;52:200–3.View ArticleGoogle Scholar
  51. Sorscher SM. Acinar Cell Carcinoma Responding to Carboplatin/Etoposide Chemotherapy. J Gastrointest Cancer 2011;43 Supplement 1:S2-3.Google Scholar
  52. Lowery MA, Klimstra DS, Shia J, Yu KH, Allen PJ, Brennan MF, O’Reilly EM. Acinar Cell Carcinoma of the Pancreas: New Genetic and Treatment Insights into a Rare Malignancy. The Oncologist. 2011;16:1714–20.Google Scholar
  53. Mahawish K, Iyasere IT. Pancreatic panniculitis. BMJ Case Rep. 2014. doi:10.1136/bcr-2014-204290.Google Scholar
  54. Nishikawa Y, Sakuma Y, Yazumi S. Xanthogranulomatous cholecystitis-induced pancreatic panniculitis. Intern Med Tokyo Jpn. 2014;53:1715–6.View ArticleGoogle Scholar
  55. Holt BA, Hawes R, Varadarajulu S. Hemosuccus pancreaticus caused by superior mesenteric artery fistula presenting as pancreatic panniculitis and anemia. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2014;12:e97–98.Google Scholar
  56. Makhoul E, Yazbeck C, Urbain D, Mana F, Mahanna S, Akiki B, Elias E. Pancreatic panniculitis: a rare complication of pancreatitis secondary to ERCP. Arab J Gastroenterol Off Publ Pan-Arab Assoc Gastroenterol. 2014;15:38–9.Google Scholar
  57. Guo ZZ, Huang ZY, Huang LB, Tang CW. Pancreatic panniculitis in acute pancreatitis. J Dig Dis. 2014;15:327–30.PubMedView ArticleGoogle Scholar
  58. Sotoude H, Mozafari R, Mohebbi Z, Mirfazaelian H. Pancreatic panniculitis. Am J Emerg Med. 2014;32:944. e1–2.PubMedView ArticleGoogle Scholar
  59. Oh CC, Lee HY, Chan MFM, Thirumoorthy T. Pancreatic panniculitis following endoscopic retrograde cholangiopancreatography. Skinmed. 2013;11:173–4.PubMedGoogle Scholar
  60. Rongioletti F, Caputo V. Pancreatic panniculitis. G Ital Dermatol E Venereol Organo Uff Soc Ital Dermatol E Sifilogr. 2013;148:419–25.Google Scholar
  61. Gorovoy IR, McSorley J, Gorovoy JB. Pancreatic panniculitis secondary to acinar cell carcinoma of the pancreas. Cutis. 2013;91:186–90.PubMedGoogle Scholar
  62. Pfaundler N, Kessebohm K, Blum R, Stieger M, Stickel F. Adding pancreatic panniculitis to the panel of skin lesions associated with triple therapy of chronic hepatitis C. Liver Int. 2013;33:648–9.PubMedView ArticleGoogle Scholar
  63. Sharma M, Reddy DN, Kiat TC. Endoscopic Retrograde Cholangiopancreatography as a Risk Factor for Pancreatic Panniculitis in a Post-Liver Transplant Patient. ACG Case Rep J. 2014;2:36–8.PubMedPubMed CentralView ArticleGoogle Scholar
  64. Burland L, Green BL. A cutaneous manifestation of intra-abdominal disease. BMJ. 2014;349:g5492–2.Google Scholar
  65. Souza FH, Siqueira EBD, Mesquita L, Fabricio LZ, Tuon FF. Pancreatic panniculitis as the first manifestation of visceral disease--case report. An Bras Dermatol. 2011;86(4 Suppl 1):S125–128.PubMedView ArticleGoogle Scholar
  66. Colantonio S, Beecker J. Pancreatic panniculitis. CMAJ Can Med Assoc J J Assoc Medicale Can. 2012;184:E159.View ArticleGoogle Scholar
  67. Rose C, Leverkus M, Fleischer M, Shimanovich I. Histopathology of panniculitis--aspects of biopsy techniques and difficulties in diagnosis. J Dtsch Dermatol Ges J Ger Soc Dermatol JDDG. 2012;10:421–5.Google Scholar
  68. Vasdev V, Bhakuni D, Narayanan K, Jain R. Intramedullary fat necrosis, polyarthritis and panniculitis with pancreatic tumor: a case report. Int J Rheum Dis. 2010;13:e74–78.PubMedView ArticleGoogle Scholar
  69. Jacobson-Dunlop E, Takiguchi R, White CR, White KP. Fatal pancreatitis presenting as pancreatic panniculitis without enzyme elevation. J Cutan Pathol. 2011;38:455–7.PubMedView ArticleGoogle Scholar
  70. Stauffer JA, Bray JM, Nakhleh RE, Bowers SP. Image of the month. Acinar cell carcinoma. Arch Surg Chic Ill 1960. 2011;146:1099–100.Google Scholar
  71. Kirkland EB, Sachdev R, Kim J, Peng D. Early pancreatic panniculitis associated with HELLP syndrome and acute fatty liver of pregnancy. J Cutan Pathol. 2011;38:814–7.PubMedGoogle Scholar
  72. Zheng ZJ, Gong J, Xiang GM, Mai G, Liu XB. Pancreatic panniculitis associated with acinar cell carcinoma of the pancreas: a case report. Ann Dermatol. 2011;23:225–8.PubMedPubMed CentralView ArticleGoogle Scholar
  73. Lueangarun S, Sittinamsuwan P, Mahakkanukrauh B, Pattanaprichakul P, Pongprasobchai S. Pancreatic panniculitis: a cutaneous presentation as an initial clue to the diagnosis of pancreatic cancer. J Med Assoc Thail Chotmaihet Thangphaet. 2011;94 Suppl 1:S253–257.Google Scholar
  74. Qian D-H, Shen B-Y, Zhan X, Peng C, Cheng D. Liquefying panniculitis associated with intraductal papillary mucinous neoplasm. JRSM Short Rep. 2011;2:38.PubMedPubMed CentralView ArticleGoogle Scholar
  75. Moro M, Moletta L, Blandamura S, Sperti C. Acinar cell carcinoma of the pancreas associated with subcutaneous panniculitis. JOP J Pancreas. 2011;12:292–6.Google Scholar
  76. Prikis M, Norman D, Rayhill S, Olyaei A, Troxell M, Mittalhenkle A. Preserved endocrine function in a pancreas transplant recipient with pancreatic panniculitis and antibody-mediated rejection. Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg. 2010;10:2717–22.View ArticleGoogle Scholar
  77. Gandhi RK, Bechtel M, Peters S, Zirwas M, Darabi K. Pancreatic panniculitis in a patient with BRCA2 mutation and metastatic pancreatic adenocarcinoma. Int J Dermatol. 2010;49:1419–20.PubMedView ArticleGoogle Scholar
  78. Porcu A, Tilocca PL, Pilo L, Ruiu F, Dettori G. Pancreatic pseudocyst-inferior vena cava fistula causing caval stenosis, left renal vein thrombosis, subcutaneous fat necrosis, arthritis and dysfibrinogenemia. Ann Ital Chir. 2010;81:215–20.PubMedGoogle Scholar
  79. Rao AG, Danturty I. Pancreatic panniculitis in a child. Indian J Dermatol. 2010;55:185–7.PubMedPubMed CentralView ArticleGoogle Scholar
  80. Fraisse T, Boutet O, Tron A-M, Prieur E. Pancreatitis, panniculitis, polyarthritis syndrome: An unusual cause of destructive polyarthritis. Joint Bone Spine. 2010;77:617–8.PubMedView ArticleGoogle Scholar
  81. Tran KT, Hughes S, Cockerell CJ, Yancey KB. Tender erythematous plaques on the legs. Pancreatic panniculitis (PP). Clin Exp Dermatol. 2010;35:e65–66.PubMedView ArticleGoogle Scholar
  82. Harris MD, Bucobo JC, Buscaglia JM. Pancreatitis, panniculitis, polyarthritis syndrome successfully treated with EUS-guided cyst-gastrostomy. Gastrointest Endosc. 2010;72:456–8.PubMedView ArticleGoogle Scholar
  83. Beyazıt H, Aydin O, Demirkesen C, Derin D, Süt P, Emre A, Mandel N. Pancreatic panniculitis as the first manifestation of the pancreatic involvement during the course of a gastric adenocarcinoma. Med Oncol Northwood Lond Engl. 2011;28:137–9.Google Scholar
  84. Kuwatani M, Kawakami H, Yamada Y. Osteonecrosis and panniculitis as life-threatening signs. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2010;8:e52–53.Google Scholar
  85. Chee C. Panniculitis in a patient presenting with a pancreatic tumour and polyarthritis: a case report. J Med Case Reports. 2009;3:7331.PubMed CentralView ArticleGoogle Scholar
  86. Chopra R, Chhabra S, Thami GP, Punia RPS. Panniculitis: clinical overlap and the significance of biopsy findings. J Cutan Pathol. 2010;37:49–58.PubMedView ArticleGoogle Scholar
  87. Farrant P, Abu-Nab Z, Hextall J. Tender erythematous nodules on the lower limb. Clin Exp Dermatol. 2009;34:549–51.PubMedView ArticleGoogle Scholar
  88. Madarasingha NP, Satgurunathan K, Fernando R. Pancreatic panniculitis: A rare form of panniculitis. Dermatol Online J. 2009;15:17.PubMedGoogle Scholar
  89. Chiewchengchol D, Wananukul S, Noppakun N. Pancreatic panniculitis caused by L-asparaginase induced acute pancreatitis in a child with acute lymphoblastic leukemia. Pediatr Dermatol. 2009;26:47–9.PubMedView ArticleGoogle Scholar
  90. Poelman SM, Nguyen K. Pancreatic panniculitis associated with acinar cell pancreatic carcinoma. J Cutan Med Surg. 2008;12:38–42.PubMedGoogle Scholar
  91. Lakhani A, Maas L. Necrotizing panniculitis: a skin condition associated with acinar cell carcinoma of the pancreas. South Med J. 2008;101:554–5.PubMedView ArticleGoogle Scholar
  92. Sagi L, Amichai B, Barzilai A, Weitzen R, Trau H. Pancreatic panniculitis and carcinoma of the pancreas. Clin Exp Dermatol. 2009;34:e205–207.PubMedView ArticleGoogle Scholar
  93. Lee WS, Kim MY, Kim SW, Paik CN, Kim HO, Park YM. Fatal Pancreatic Panniculitis Associated with Acute Pancreatitis: A Case Report. J Korean Med Sci. 2007;22:914–7.PubMedPubMed CentralView ArticleGoogle Scholar
  94. Suwattee P, Cham PMH, Pope E, Ho N. Pancreatic panniculitis in a 4-year-old child with nephrotic syndrome. Pediatr Dermatol. 2007;24:659–60.PubMedView ArticleGoogle Scholar
  95. Bagazgoitia L, Alonso T, Ríos-Buceta L, Ruedas A, Carrillo R, Muñoz-Zato E. Pancreatic panniculitis: an atypical clinical presentation. Eur J Dermatol EJD. 2009;19:191–2.PubMedGoogle Scholar
  96. Shehan JM, Kalaaji AN. Pancreatic panniculitis due to pancreatic carcinoma. Mayo Clin Proc. 2005;80:822.PubMedView ArticleGoogle Scholar
  97. Johnson MA, Kannan DG, Balachandar TG, Jeswanth S, Rajendran S, Surendran R. Acute septal panniculitis. A cutaneous marker of a very early stage of pancreatic panniculitis indicating acute pancreatitis. J Pancreas. 2005;6:334–8.Google Scholar
  98. Gahr N, Technau K, Ghanem N. Intraductal papillary mucinous adenoma of the pancreas presenting with lobular panniculitis. Eur Radiol. 2006;16:1397–8.PubMedView ArticleGoogle Scholar
  99. Price-Forbes AN, Filer A, Udeshi UL, Rai A. Progression of imaging in pancreatitis panniculitis polyarthritis (PPP) syndrome. Scand J Rheumatol. 2006;35:72–4.PubMedView ArticleGoogle Scholar
  100. Pike JL, Rice JC, Sanchez RL, Kelly EB, Kelly BC. Pancreatic panniculitis associated with allograft pancreatitis and rejection in a simultaneous pancreas-kidney transplant recipient. Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg. 2006;6:2502–5.View ArticleGoogle Scholar
  101. Fernández-Jorge B, García-Silva J, Almagro M, Ruzo JS, Rey EC, Fonseca E. Pancreatic panniculitis after endoscopic retrograde pancreatography with sphincterotomy. Am J Gastroenterol. 2007;102:463–4.PubMedView ArticleGoogle Scholar
  102. Kaufman HL, Harandi A, Watson MC, Carter EL, DeRaffele G, Shahid M, Fine RL. Panniculitis after vaccination against CEA and MUC1 in a patient with pancreatic cancer. Lancet Oncol. 2005;6:62–3.Google Scholar
  103. Van der Zee J-A, van Hillegersberg R, Toonstra J, Gouma DJ. Subcutaneous nodules pointing towards pancreatic disease: pancreatic panniculitis. Dig Surg. 2004;21:275–6.PubMedView ArticleGoogle Scholar
  104. Menon P, Kulshreshta R. Pancreatitis with panniculitis and arthritis: a rare association. Pediatr Surg Int. 2004;20:161–2.PubMedView ArticleGoogle Scholar
  105. Preiss JC, Faiss S, Loddenkemper C, Zeitz M, Duchmann R. Pancreatic panniculitis in an 88-year-old man with neuroendocrine carcinoma. Digestion. 2002;66:193–6.PubMedView ArticleGoogle Scholar
  106. Echeverría CM, Fortunato LP, Stengel FM, Laurini J, Díaz C. Pancreatic panniculitis in a kidney transplant recipient. Int J Dermatol. 2001;40:751–3.PubMedView ArticleGoogle Scholar
  107. Mourad FH, Hannoush HM, Bahlawan M, Uthman I, Uthman S. Panniculitis and arthritis as the presenting manifestation of chronic pancreatitis. J Clin Gastroenterol. 2001;32:259–61.PubMedView ArticleGoogle Scholar
  108. Wang M-C, Sung J-M, Chen F-F, Lee W-C, Huang J-J. Pancreatic Panniculitis in a Renal Transplant Recipient. Nephron. 2000;86:550–1.PubMedView ArticleGoogle Scholar
  109. Cutlan RT, Wesche WA, Jenkins JJ, Chesney TM. A fatal case of pancreatic panniculitis presenting in a young patient with systemic lupus. J Cutan Pathol. 2000;27:466–71.PubMedView ArticleGoogle Scholar
  110. Heykarts B, Anseeuw M, Degreef H. Panniculitis caused by acinous pancreatic carcinoma. Dermatol Basel Switz. 1999;198:182–3.View ArticleGoogle Scholar
  111. López A, García-Estañ J, Marras C, Castaño M, Rojas MJ, Garre C, Gómez J. Pancreatitis associated with pleural-mediastinal pseudocyst, panniculitis and polyarthritis. Clin Rheumatol. 1998;17:335–9.Google Scholar
  112. Brown R, Buckley R, Kelley M. Pancreatic panniculitis. J Clin Oncol Off J Am Soc Clin Oncol. 1997;15:3418–9.View ArticleGoogle Scholar
  113. Kuerer H, Shim H, Pertsemlidis D, Unger P. Functioning pancreatic acinar cell carcinoma: immunohistochemical and ultrastructural analyses. Am J Clin Oncol. 1997;20:101–7.PubMedView ArticleGoogle Scholar
  114. Zellman GL. Pancreatic panniculitis. J Am Acad Dermatol. 1996;35(2, Part 1):282–3.PubMedView ArticleGoogle Scholar
  115. Ball NJ, Adams SP, Marx LH, Enta T. Possible origin of pancreatic fat necrosis as a septal panniculitis. J Am Acad Dermatol. 1996;34(2 Pt 2):362–4.PubMedView ArticleGoogle Scholar
  116. Lambiase P, Seery JP, Taylor-Robinson SD, Thompson JN, Hughes JM, Walters JR. Resolution of panniculitis after placement of pancreatic duct stent in chronic pancreatitis. Am J Gastroenterol. 1996;91:1835–7.PubMedGoogle Scholar
  117. Martínez-Escribano JA, Pedro F, Sabater V, Quecedo E, Navarro V, Aliaga A. Acute exanthem and pancreatic panniculitis in a patient with primary HIV infection and haemophagocytic syndrome. Br J Dermatol. 1996;134:804–7.PubMedView ArticleGoogle Scholar
  118. Sanchez MH, Fernandez RS, Gomez-Calcerrada MR. Single-nodule pancreatic panniculitis. Dermatol Basel Switz. 1996;193:269.View ArticleGoogle Scholar
  119. Feuer J, Spiera H, Phelps RG, Shim H. Panniculitis of pancreatic disease masquerading as systemic lupus erythematosus panniculitis. J Rheumatol. 1995;22:2170–2.PubMedGoogle Scholar
  120. Francombe J, Kingsnorth AN, Tunn E. Panniculitis, arthritis and pancreatitis. Br J Rheumatol. 1995;34:680–3.PubMedView ArticleGoogle Scholar
  121. Rodriguez M, Lopez GL, Prieto P, Fernandez L, Willisch A, Arce M. Massive subcutaneous and intraosseous fat necrosis associated with pancreatitis. Natural evolution of the radiographic picture. Clin Rheumatol. 1997;16:199–203.PubMedView ArticleGoogle Scholar
  122. Cheng KS, Stansby G, Law N, Gardham R. Recurrent panniculitis as the first clinical manifestation of recurrent acute pancreatitis secondary to cholelithiasis. J R Soc Med. 1996;89:105P–6P.PubMedPubMed CentralGoogle Scholar
  123. Cevasco M, Rodriguez JR, Fernandez-del Castillo C. Clinical Challenges and Images in GI. Gastroenterology. 2008;135:1054–433.PubMedView ArticleGoogle Scholar
  124. Sahani D, Prasad SR, Maher M, Warshaw AL, Hahn PF, Saini S. Functioning acinar cell pancreatic carcinoma: diagnosis on mangafodipir trisodium (Mn-DPDP)-enhanced MRI. J Comput Assist Tomogr. 2002;26:126–8.PubMedView ArticleGoogle Scholar
  125. Agarwal S, Nelson JE, Stevens SR, Gilliam AC. An unusual case of cutaneous pancreatic fat necrosis. J Cutan Med Surg. 2002;6:16–8.PubMedView ArticleGoogle Scholar
  126. Omland SH, Ekenberg C, Henrik-Nielsen R, Friis-Møller A. Pancreatic panniculitis complicated by infection with Corynebacterium tuberculostearicum: A case report. IDCases. 2014;1:45–6.PubMedPubMed CentralView ArticleGoogle Scholar
  127. Choi H-J, Kim K-J, Lee M-W, Choi J-H, Moon K-C, Koh J-K. Pancreatic carcinoma-associated subcutaneous fat necrosis improved by palliative surgery. J Dermatol. 2004;31:584–6.PubMedView ArticleGoogle Scholar
  128. Federman DG, McNiff JM, Kirsner RS. Pancreatic panniculitis. Wounds 2004;16:140-146.Google Scholar
  129. Stanford AR, Mezebish DS, Cobb MW. Nodular fat necrosis associated with lupus-induced pancreatitis. Int J Dermatol. 1997;36:856–8.PubMedView ArticleGoogle Scholar
  130. Hammar A-M, Sand J, Lumio J, Hirn M, Honkonen S, Tuominen L, Nordback I. Pancreatic pseudocystportal vein fistula manifests as residivating oligoarthritis, subcutaneous, bursal and osseal necrosis: a case report and review of literature. Hepatogastroenterology. 2002;49:273–8.Google Scholar
  131. Shbeeb MI, Duffy J, Bjornsson J, Ashby AM, Matteson EL. Subcutaneous fat necrosis and polyarthritis associated with pancreatic disease. Arthritis Rheum. 1996;39:1922–5.PubMedView ArticleGoogle Scholar
  132. Carasso S, Oren I, Alroy G, Krivoy N. Disseminated fat necrosis with asymptomatic pancreatitis: a case report and review of the literature. Am J Med Sci. 2000;319:68–72.PubMedView ArticleGoogle Scholar
  133. Jovanovic M, Golusin Z, Petrovic A, Vuckovic N, Brkic S, Sotirovic-Senicar S, Petrovic K. Lobular panniculitis: A manifestation of pancreatic tumor with fatal outcome. Arch Oncol. 2005;13:153–5.Google Scholar
  134. Mehringer S, Vogt T, Jabusch H-C, Kroiβ M, Fürst A, Schölmerich J, Messmann H. Treatment of panniculitis in chronic pancreatitis by interventional endoscopy following extracorporeal lithotripsy. Gastrointest Endosc. 2001;53:104–7.Google Scholar
  135. Azar L, Chatterjee S, Schils J. Pancreatitis, polyarthritis and panniculitis syndrome. Jt Bone Spine Rev Rhum. 2014;81:184.View ArticleGoogle Scholar
  136. Tucker C, Owen C, Malone J, Callen J. Pancreatic panniculitis mimicking septic emboli in a 7-year-old boy with abdominal compartment syndrome. J Am Acad Dermatol. 2014;70:AB148.Google Scholar
  137. Ahn BC, Lee J, Suh KJ, Chun KA, Sohn SK, Lee K, Kim CK. Intramedullary fat necrosis of multiple bones associated with pancreatitis. J Nucl Med Off Publ Soc Nucl Med. 1998;39:1401–4.Google Scholar
  138. Karasick D, Schweitzer ME. Case 4: intraosseous fat necrosis associated with pancreatitis. Radiology. 1998;209:521–4.PubMedView ArticleGoogle Scholar
  139. Kotilainen P, Saario R, Mattila K, Nylamo E, Aho H. Intraosseous fat necrosis simulating septic arthritis and osteomyelitis in a patient with chronic pancreatitis. Arch Orthop Trauma Surg. 1998;118:174–5.PubMedView ArticleGoogle Scholar
  140. L’Hirondel JL, Fournier L, Fretille A, Denizet D, Loyau G. Intraosseous fat necrosis and metaphyseal osteonecrosis in a patient with chronic pancreatitis: MR imaging and CT scanning. Clin Exp Rheumatol. 1994;12:191–4.PubMedGoogle Scholar
  141. Ohno Y, Le Pavoux A, Saeki H, Asahina A, Tamaki K. A case of subcutaneous nodular fat necrosis with lipase-secreting acinar cell carcinoma. Int J Dermatol. 2003;42:384–5.PubMedView ArticleGoogle Scholar
  142. Klimstra DS, Adsay NV. Acinar Cell Carcinoma of the Pancreas: A Case Associated With the Lipase Hypersecretion Syndrome. Pathol Case Rev. 2001;6:121–6.View ArticleGoogle Scholar
  143. Sielaff T. The telltale rash: a man with pretibial erythema. Minn Med. 2008;91:45–6.PubMedGoogle Scholar

Copyright

© Zundler et al. 2016

Advertisement